共 50 条
- [21] A double-blind, double-dummy, randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrenceGASTROENTEROLOGY, 2008, 134 (04) : A70 - A70Reinisch, WalterAngelberger, SieglindePetritsch, WolfgangHerrlinger, KlausShonova, OlgaLukas, MilanBar-Meir, SimonSchwab, MatthiasGreinwald, RolandMueller, RalphStange, Eduard
- [22] AZATHIOPRINE VS MESALAMINE FOR PREVENTION OF POST-OPERATIVE CLINICAL RELAPSE IN CROHN'S DISEASE PATIENTS WITH SEVERE ENDOSCOPIC RECURRENCE: DATA ON EFFICACY AND SAFETY FROM AN IG-IBD MULTICENTER RANDOMIZED DOUBLE-BLIND DOUBLE-DUMMY TRIALDIGESTIVE AND LIVER DISEASE, 2019, 51 : E232 - E232Orlando, A.Mocciaro, F.Ventimiglia, M.Renna, S.Scimeca, D.Rispo, A.Scribano, M. L.Testa, A.Aratari, A.Bossa, F.Angelucci, E.Onali, S.Cappello, M.Giunta, M.Castiglione, F.Papi, C.Annese, V.Biancone, L.Kohn, A.Di Mitri, R.Cottone, M.
- [23] Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialGUT, 2010, 59 (06) : 752 - 759Reinisch, WalterAngelberger, SieglindePetritsch, WolfgangShonova, OlgaLukas, MilanBar-Meir, SimonTeml, AlexanderSchaeffeler, ElkeSchwab, MatthiasDilger, KarinGreinwald, RolandMueller, RalphStange, Eduard F.Herrlinger, Klaus R.
- [24] Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to InfliximabGASTROENTEROLOGY, 2009, 136 (05) : A27 - A27Sandborn, William J.Vermeire, SeverineD'Haens, Geert R.Colombel, Jean-FredericFedorak, Richard N.Spehlmann, Martina E.Wolf, Douglas C.Abreu, Maria T.Mitchev, KrassimirJamoul, CorinneRutgeerts, Paul J.
- [25] Double-blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5-ASA) for prevention of postoperative endoscopic recurrence in Crohn's diseaseGASTROENTEROLOGY, 2006, 130 (04) : A480 - A481Herfarth, HansObermeier, FlorianTjaden, ChristinLukas, MilanSerclova, ZuzanaDignass, Axel U.Ludwig, DietherMueller, RalphSchoelmerich, Juergern
- [26] The efficacy and safety of abatacept or infliximab in ra patients with an inadequate response to MTX: Results from a 1-year double-blind, randomized, placebo-controlled trialJOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1627 - 1627Bessette, LouisSchiff, MichaelKieserman, Mauro
- [27] A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week ResultsARTHRITIS & RHEUMATOLOGY, 2015, 67Choe, Jung-YoonProdanovic, NenadNiebrzydowski, JaroslawStaykov, IvanDokoupilova, EvaBaranauskaite, AstaYatsyshyn, RomanMekic, MevludinPorawska, WieslawaCiferska, HanaJedrychowicz-Rosiak, KrystynaZielinska, AgnieszkaChoi, JasmineRho, Young HeeSmolen, Josef S.
- [28] Efficacy of abatacept or infliximab treatment in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a 1-year double-blind, randomized, placebo-controlled trialJOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1178 - 1179Bessette, L.Homik, J.Dougados, M.Keiserman, M.Codding, C.Songcharoen, S.Berman, A.Nayiager, S.Saldate, C.Aranda, R.Becker, J.Li, T.Lin, C.Cornet, P. L. N.Schiff, M.
- [29] Efficacy of abatacept or infliximab treatment in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a 1-year double-blind, randomized, placebo-controlled trialANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 88 - 88Dougados, M.Keiserman, M.Codding, C.Songcharoen, S.Berman, A.Nayiager, S.Saldate, C.Aranda, R.Becker, J.Li, T.Lin, C.Cornet, R. L. N.Schiff, M.
- [30] The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind, randomized, placebo-controlled trial.ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4117 - 4118Schiff, M.Keiserman, M.Codding, C.Songcharoen, S.Berman, A.Nayiager, S.Saldate, S.Aranda, R.Becker, J-CLin, C.Cornet, L. N.Dougados, M.